{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:02:00Z","timestamp":1792803720005,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ajog.2026.02.046","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:17:44Z","timestamp":1772641064000},"page":"78-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Venous thromboembolism with combined oral contraceptives based on estrogen and progestin content: a disproportionality analysis of the United States Food and Drug Administration Adverse Event Reporting System database"],"prefix":"10.1016","volume":"235","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7915-8147","authenticated-orcid":false,"given":"Lucie","family":"Raskin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Didembourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Dogne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9d\u00e9a","family":"Locquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell D.","family":"Creinin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Beaudart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7644-5298","authenticated-orcid":false,"given":"Jonathan","family":"Douxfils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2026.02.046_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.769187","article-title":"Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk","volume":"12","author":"Morimont","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ajog.2026.02.046_bib6","first-page":"CD010813","article-title":"Combined oral contraceptives: venous thrombosis","volume":"2014","author":"de Bastos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajog.2026.02.046_bib7","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1055\/s-0040-1714140","article-title":"Oral contraceptives and venous thromboembolism: focus on testing that may enable prediction and assessment of the risk","volume":"46","author":"Douxfils","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ajog.2026.02.046_bib8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.contraception.2020.08.015","article-title":"Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters","volume":"102","author":"Douxfils","year":"2020","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2026.02.046_bib9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/clinem\/dgac511","article-title":"Low thrombin generation in users of a contraceptive containing estetrol and drospirenone","volume":"108","author":"Morimont","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ajog.2026.02.046_bib10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3109\/13625187.2011.604450","article-title":"Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17beta-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism","volume":"16","author":"Agren","year":"2011","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.ajog.2026.02.046_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/11591200-000000000-00000","article-title":"Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate\/dienogest versus ethinylestradiol\/levonorgestrel","volume":"11","author":"Klipping","year":"2011","journal-title":"Drugs in R&D"},{"key":"10.1016\/j.ajog.2026.02.046_bib12","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/jth.14745","article-title":"Proof of concept of a new scale for the harmonization and the standardization of the ETP-based APC resistance","volume":"18","author":"Morimont","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ajog.2026.02.046_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1428597","article-title":"Are natural estrogens used in contraception at lower risk of venous thromboembolism than synthetic ones? A systematic literature review and meta-analysis","volume":"15","author":"Douxfils","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ajog.2026.02.046_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2024.110727","article-title":"Lower reporting of venous thromboembolisms events with natural estrogen-based combined oral contraceptives compared to ethinylestradiol-containing pills: a disproportionality analysis of the eudravigilance database","volume":"142","author":"Didembourg","year":"2025","journal-title":"Contraception"},{"key":"10.1016\/j.ajog.2026.02.046_bib15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ajog.2026.02.046_bib16","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ajog.2026.02.046_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2024","journal-title":"Front Drug Saf Regul"},{"key":"10.1016\/j.ajog.2026.02.046_bib18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.thromres.2020.08.006","article-title":"Letter to the Editors-in-Chief in response to the article of Abou-Ismail, et al. entitled \"Estrogen and thrombosis: a bench to bedside review\" (Thrombosis Research 192 (2020) 40-51)","volume":"193","author":"Morimont","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.ajog.2026.02.046_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/10760296241286514","article-title":"Impact of estetrol combined with drospirenone on blood coagulation and fibrinolysis in patients with endometriosis: a multicenter, randomized, open-label, active-controlled, parallel-group study","volume":"30","author":"Kobayashi","year":"2024","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.ajog.2026.02.046_bib20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1515\/cclm-2019-0471","article-title":"Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need","volume":"58","author":"Douxfils","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.ajog.2026.02.046_bib21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jtha.2022.10.014","article-title":"Factor V Leiden-independent activated protein C resistance: communication from the plasma coagulation inhibitors subcommittee of the International Society on Thrombosis and Haemostasis Scientific and Standardisation Committee","volume":"21","author":"Moore","year":"2023","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.ajog.2026.02.046_bib22","article-title":"Thromboembolic events associated with combined oral contraceptives: a real-world study based on the FDA adverse event reporting system (FAERS) database","author":"Liu","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ajog.2026.02.046_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejogrb.2024.07.048","article-title":"Safety assessment of Yasmin: Real-World adverse event analysis using the FAERS database","volume":"301","author":"Xu","year":"2024","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2026.02.046_bib24","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ejogrb.2024.10.053","article-title":"Errors in the use of the FAERS database to assess the safety of Yasmin","volume":"303","author":"Creinin","year":"2024","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2026.02.046_bib25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/13625187.2021.1987410","article-title":"Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17beta-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism","volume":"26","author":"Reed","year":"2021","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.ajog.2026.02.046_bib26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/AOG.0000000000005509","article-title":"Venous thromboembolic risk of Estradiol valerate-dienogest compared with ethinyl estradiol-levonorgestrel combined oral contraceptives","volume":"143","author":"Bauerfeind","year":"2024","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2026.02.046_bib27","first-page":"117","volume":"22","author":"Douxfils","year":"2023","journal-title":"Prz Menopauzalny"},{"key":"10.1016\/j.ajog.2026.02.046_bib28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.thromres.2011.07.050","article-title":"Socioeconomic and occupational risk factors for venous thromboembolism in Sweden: a nationwide epidemiological study","volume":"129","author":"Zoller","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.ajog.2026.02.046_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2025.110861","article-title":"Estetrol\/Drospirenone safety in a population with cardiovascular risk factors","volume":"146","author":"Creinin","year":"2025","journal-title":"Contraception"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937826001298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937826001298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:52:58Z","timestamp":1781628778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937826001298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0002937826001298"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2026.02.046","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venous thromboembolism with combined oral contraceptives based on estrogen and progestin content: a disproportionality analysis of the United States Food and Drug Administration Adverse Event Reporting System database","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2026.02.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}